HCA Healthcare Inc: UBS Increases Target Price from $598 to $635
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy HCA?
Source: moomoo
Healthcare Company Price Increase: A healthcare company has raised its target price to $635 from $598.
Market Impact: This price adjustment may influence investor sentiment and market dynamics related to the company's stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HCA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HCA
Wall Street analysts forecast HCA stock price to fall
19 Analyst Rating
13 Buy
5 Hold
1 Sell
Moderate Buy
Current: 525.880
Low
420.00
Averages
491.89
High
525.00
Current: 525.880
Low
420.00
Averages
491.89
High
525.00
About HCA
HCA Healthcare, Inc. is a health care services company. It owns, manages or operates hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, comprehensive rehabilitation and physical therapy centers, hospices, and various other facilities. Its general, acute care hospitals provide a full range of services to accommodate such medical specialties as internal medicine, general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics, as well as diagnostic and emergency services. Its behavioral hospitals provide a full range of mental health care services through inpatient, partial hospitalization and outpatient settings. It operates approximately 190 hospitals and 2,400 ambulatory sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics, in 20 states and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
HCA Healthcare Again Named on Fortune's Most Admired Companies List
- Industry Leadership: HCA Healthcare has once again been ranked No. 1 in its industry on Fortune's 2026 World's Most Admired Companies list, highlighting its exceptional performance and leadership in healthcare services, thereby reinforcing its competitive advantage in the market.
- Research and Innovation Expansion: The HCA Healthcare Research Institute expanded to 54 sites in 2025, enrolling over 6,600 patients in more than 520 active studies, demonstrating the company's ongoing commitment to advancing medical research and improving patient outcomes.
- Employee Education Investment: Last year, the company provided over $40 million in tuition assistance to more than 11,700 colleagues, with 24% of them using the funds to pursue nursing degrees, reflecting HCA's dedication to employee professional development and support.
- Leadership Development Program: Since its inception, the HCA Healthcare Leadership Institute has graduated over 40,140 colleagues, with more than 9,200 graduating in 2025, indicating the company's strategic investment in cultivating future leaders and enhancing team management capabilities.
See More
HCA Healthcare Inc: UBS Increases Target Price from $598 to $635
Healthcare Company Price Increase: A healthcare company has raised its target price to $635 from $598.
Market Impact: This price adjustment may influence investor sentiment and market dynamics related to the company's stock.
See More
HCA Healthcare Maintains Growth Momentum Amid Regulatory Challenges
- Strong Financial Performance: HCA Healthcare achieved a 6.7% revenue increase in Q4 2025, reaching $19.5 billion, driven by healthy growth in hospital admissions, while adjusted earnings per share surged 28.8% to $8.01, demonstrating robust profitability in the healthcare sector.
- Market Outlook Analysis: Although the fiscal 2026 revenue guidance ranges from $76.5 billion to $80 billion, implying a modest 3.5% year-over-year growth, the sales growth remains impressive considering the rising healthcare demand and regulatory uncertainties, showcasing HCA's adaptability.
- Investment Opportunities: With the global population aging, HCA Healthcare anticipates higher medical care demand over the next decade, and its initiatives to improve patient outcomes are helping to expand market share, strengthening relationships with physicians, patients, and third-party payers.
- Regulatory Challenge Response: Despite facing regulatory uncertainties, HCA Healthcare continues to demonstrate solid performance, and while volatility may occur, its strong position in the healthcare industry and growth opportunities suggest the stock could deliver above-average returns in the long run.
See More
HCA Healthcare Reports Strong Earnings and Positive Guidance
- Strong Financial Performance: HCA Healthcare reported a revenue of $19.5 billion for Q4 2025, reflecting a 6.7% year-over-year increase, while adjusted earnings per share surged by 28.8% to $8.01, indicating robust financial health driven by increased hospital admissions.
- 2026 Revenue Guidance: Although HCA expects revenue between $76.5 billion and $80 billion for 2026, translating to a modest growth rate of approximately 3.5%, this performance is noteworthy given the ongoing regulatory uncertainties affecting the healthcare sector.
- Market Share Expansion: HCA is actively investing in AI-driven initiatives to improve patient outcomes, thereby strengthening relationships with physicians, patients, and third-party payers, which is crucial for maintaining competitive advantage in the healthcare market.
- Long-Term Growth Opportunities: With the aging global population, HCA anticipates a significant increase in healthcare demand over the next decade, and despite potential short-term volatility, the company's strong position in the healthcare industry suggests that its stock could deliver above-average returns in the long run.
See More
Analysis of PKW ETF's 52-Week Price Range
- Price Range Analysis: The PKW ETF's 52-week low is $96.10 per share, with a high of $140.10, and the current trading price at $139.62 indicates it is nearing its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and identify potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which will affect the ETF's underlying holdings and may lead to price fluctuations.
See More
HCA Healthcare Leverages AI to Enhance Operational Efficiency
- AI-Driven Staffing Tool: HCA Healthcare has launched an AI-assisted nurse staffing tool aimed at alleviating nurse shortages and burnout, thereby enhancing patient safety and optimizing scheduling efficiency; while not revolutionary, it significantly improves operational efficiency.
- Fetal Monitoring Technology Partnership: HCA Healthcare is collaborating with GE Healthcare to develop an AI-powered fetal heart rate monitor, designed to assist doctors in effectively monitoring fetal health and addressing workforce shortages, further enhancing the quality of medical services.
- Long-Term Investment Potential: With its extensive network of facilities and deep relationships with physicians and insurers, HCA Healthcare, combined with the application of AI technology, is expected to deliver solid investment returns in the future, particularly as global aging drives rising healthcare spending.
- Ongoing Technology Investment: HCA Healthcare has consistently prioritized investments in cutting-edge technology, and the introduction of AI will continue to enhance its ability to attract patients, ensuring the company maintains a competitive edge in the healthcare market.
See More
HCA Healthcare Again Named on Fortune's Most Admired Companies List
- Industry Leadership: HCA Healthcare has once again been ranked No. 1 in its industry on Fortune's 2026 World's Most Admired Companies list, highlighting its exceptional performance and leadership in healthcare services, thereby reinforcing its competitive advantage in the market.
- Research and Innovation Expansion: The HCA Healthcare Research Institute expanded to 54 sites in 2025, enrolling over 6,600 patients in more than 520 active studies, demonstrating the company's ongoing commitment to advancing medical research and improving patient outcomes.
- Employee Education Investment: Last year, the company provided over $40 million in tuition assistance to more than 11,700 colleagues, with 24% of them using the funds to pursue nursing degrees, reflecting HCA's dedication to employee professional development and support.
- Leadership Development Program: Since its inception, the HCA Healthcare Leadership Institute has graduated over 40,140 colleagues, with more than 9,200 graduating in 2025, indicating the company's strategic investment in cultivating future leaders and enhancing team management capabilities.
See More
HCA Healthcare Inc: UBS Increases Target Price from $598 to $635
Healthcare Company Price Increase: A healthcare company has raised its target price to $635 from $598.
Market Impact: This price adjustment may influence investor sentiment and market dynamics related to the company's stock.
See More
HCA Healthcare Maintains Growth Momentum Amid Regulatory Challenges
- Strong Financial Performance: HCA Healthcare achieved a 6.7% revenue increase in Q4 2025, reaching $19.5 billion, driven by healthy growth in hospital admissions, while adjusted earnings per share surged 28.8% to $8.01, demonstrating robust profitability in the healthcare sector.
- Market Outlook Analysis: Although the fiscal 2026 revenue guidance ranges from $76.5 billion to $80 billion, implying a modest 3.5% year-over-year growth, the sales growth remains impressive considering the rising healthcare demand and regulatory uncertainties, showcasing HCA's adaptability.
- Investment Opportunities: With the global population aging, HCA Healthcare anticipates higher medical care demand over the next decade, and its initiatives to improve patient outcomes are helping to expand market share, strengthening relationships with physicians, patients, and third-party payers.
- Regulatory Challenge Response: Despite facing regulatory uncertainties, HCA Healthcare continues to demonstrate solid performance, and while volatility may occur, its strong position in the healthcare industry and growth opportunities suggest the stock could deliver above-average returns in the long run.
See More
HCA Healthcare Reports Strong Earnings and Positive Guidance
- Strong Financial Performance: HCA Healthcare reported a revenue of $19.5 billion for Q4 2025, reflecting a 6.7% year-over-year increase, while adjusted earnings per share surged by 28.8% to $8.01, indicating robust financial health driven by increased hospital admissions.
- 2026 Revenue Guidance: Although HCA expects revenue between $76.5 billion and $80 billion for 2026, translating to a modest growth rate of approximately 3.5%, this performance is noteworthy given the ongoing regulatory uncertainties affecting the healthcare sector.
- Market Share Expansion: HCA is actively investing in AI-driven initiatives to improve patient outcomes, thereby strengthening relationships with physicians, patients, and third-party payers, which is crucial for maintaining competitive advantage in the healthcare market.
- Long-Term Growth Opportunities: With the aging global population, HCA anticipates a significant increase in healthcare demand over the next decade, and despite potential short-term volatility, the company's strong position in the healthcare industry suggests that its stock could deliver above-average returns in the long run.
See More
Analysis of PKW ETF's 52-Week Price Range
- Price Range Analysis: The PKW ETF's 52-week low is $96.10 per share, with a high of $140.10, and the current trading price at $139.62 indicates it is nearing its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average can provide valuable insights for investors, helping to assess market trends and identify potential buying opportunities.
- ETF Trading Mechanism: ETFs trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which will affect the ETF's underlying holdings and may lead to price fluctuations.
See More
HCA Healthcare Leverages AI to Enhance Operational Efficiency
- AI-Driven Staffing Tool: HCA Healthcare has launched an AI-assisted nurse staffing tool aimed at alleviating nurse shortages and burnout, thereby enhancing patient safety and optimizing scheduling efficiency; while not revolutionary, it significantly improves operational efficiency.
- Fetal Monitoring Technology Partnership: HCA Healthcare is collaborating with GE Healthcare to develop an AI-powered fetal heart rate monitor, designed to assist doctors in effectively monitoring fetal health and addressing workforce shortages, further enhancing the quality of medical services.
- Long-Term Investment Potential: With its extensive network of facilities and deep relationships with physicians and insurers, HCA Healthcare, combined with the application of AI technology, is expected to deliver solid investment returns in the future, particularly as global aging drives rising healthcare spending.
- Ongoing Technology Investment: HCA Healthcare has consistently prioritized investments in cutting-edge technology, and the introduction of AI will continue to enhance its ability to attract patients, ensuring the company maintains a competitive edge in the healthcare market.
See More
